Who
Patrick J. Christmas
Chief Strategy & Legal Officer
Company insider
Files Form 4 as: Chief Strategy & Legal Officer, Regenxbio; General Counsel, K-V Pharmaceutical Co.
In numbers
- Trades disclosed
- 120
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $6.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 May 2011
- Last trade
- 1 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Aug 2026filed 4 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $46K4,699 at $9.69 | filing |
| 1 Aug 2026filed 4 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $46K4,699 at $9.69 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $52K4,700 at $11.16 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $52K4,700 at $11.16 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —73,749 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,650 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,650 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —73,749 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $141K9,793 at $14.40 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $141K9,793 at $14.40 | filing |
| 1 Aug 2025filed 4 Aug 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $38K4,699 at $8.19 | filing |
| 1 Feb 2025filed 4 Apr 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $38K4,700 at $8.07 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —223,350 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $88K11,395 at $7.73 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —56,446 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —54,945 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $142K7,893 at $17.95 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —34,615 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —56,519 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $42K1,843 at $22.68 | filing |
News
Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)RGNX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Patrick J. Christmas; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.